Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Advisory Panel Supports NeuroPace’s RNS Neurostimulator

This article was originally published in The Pink Sheet Daily

Executive Summary

Neurological devices panel votes in favor of device intended to reduce epileptic seizures, despite lingering questions about the trial results.


Related Content

Research Briefs: Studies On PAD, Neurostim And STEMI Stenting
Four Firms Vie For Medicare 2014 New-Tech Add-On Payments
Adding Sense To Brain Stimulation: Medtronic, Start-Ups Pursue Opportunity


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts